FDA warned 4 companies, which are claiming that their products containing cannabidiol, can treat or cure cancer.
FDA warned 4 companies, which are claiming that their products containing cannabidiol (CBD), can treat or cure cancer.
Related: FDA warns about contaminated drugs, dietary supplements
FDA warned Greenroads Health, Natural Alchemist, That’s Natural! Marketing and Consulting, and Stanley Brothers Social Enterprises LLC, over unsubstantiated claims on more than 25 different products. The marketers said the products can prevent, reverse or cure cancer, kill cancer cells and tumors; and can treat Alzheimer’s and other serious diseases.
Related: FDA warns about deaths in cancer drug trials
“Substances that contain components of marijuana will be treated like any other products that make unproven claims to shrink cancer tumors. We don’t let companies market products that deliberately prey on sick people with baseless claims that their substance can shrink or cure cancer and we’re not going to look the other way on enforcing these principles when it comes to marijuana-containing products,” said FDA Commissioner Scott Gottlieb, MD, in a statement from FDA. “There are a growing number of effective therapies for many cancers. When people are allowed to illegally market agents that deliver no established benefit, they may steer patients away from products that have proven, anti-tumor effects that could extend lives.”
Unlike drugs approved by the FDA, manufacture of the supplements in question has not been subject to FDA review as part of the drug approval process. In addition, “there has been no FDA evaluation of whether they work, what the proper dosage is, how they could interact with other drugs, or whether they have dangerous side effects or other safety concerns,” FDA said in the statement.
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children
February 26th 2025This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic dermatitis (AD) in children aged 2 to 5 years. The PDUFA target action date of October 13, 2025, is set for its decision on the application.
Read More
FDA Accepts BLA Resubmission for Follicular Lymphoma Drug, Odronextamab
February 26th 2025The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
Read More